You have 9 free searches left this month | for more free features.

Pegylated Interferon Alfa-2b

Showing 1 - 25 of 6,096

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Essential Thrombocytopenia Trial in Tianjin (Recombinant Interferon Alpha, Pegylated interferon alfa-2b)

Recruiting
  • Essential Thrombocytopenia
  • Recombinant Interferon Alpha
  • Pegylated interferon alfa-2b
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 18, 2022

Malignant Melanoma Trial in San Diego, Memphis, Houston (Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b)

Active, not recruiting
  • Malignant Melanoma
  • Peginterferon alfa-2b
  • +2 more
  • San Diego, California
  • +2 more
Apr 1, 2022

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Mar 28, 2022

Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas Trial in Atlanta (Pegylated interferon alpha-2b)

Completed
  • Juvenile Pilocytic Astrocytomas
  • Optic Pathway Gliomas
  • Pegylated interferon alpha-2b
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Jan 18, 2022

Adult T-cell Leukemia-Lymphoma, ATLL Trial in Miami (Belinostat, Zidovudine, Interferon-Alfa-2b)

Recruiting
  • Adult T-cell Leukemia-Lymphoma
  • ATLL
  • Miami, Florida
    University of Miami
Jan 24, 2022

Chronic Hepatitis B Trial in Shanghai (Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets)

Not yet recruiting
  • Chronic Hepatitis B
  • Shanghai, Shanghai, China
  • +1 more
Feb 16, 2022

Hematological Tumors, Recurrence Trial in Shanghai (Peg interferon alfa-2b)

Recruiting
  • Hematological Neoplasms
  • Recurrence
  • Peg interferon alfa-2b
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University Affilated First People's Hospital
Oct 10, 2021

Chronic Hepatitis B Trial in Worldwide (VIR-2218, pegylated interferon-alfa 2a)

Active, not recruiting
  • Chronic Hepatitis B
  • Birtinya, Queensland, Australia
  • +21 more
Dec 20, 2021

HIV, Hepatitis C Trial in United States (Ribavirin, Aldesleukin, Peginterferon alfa-2b)

Completed
  • HIV Infections
  • Hepatitis C
  • Los Angeles, California
  • +7 more
Oct 28, 2021

HIV, Hepatitis C Trial in Puerto Rico, United States (Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC))

Completed
  • HIV Infections
  • Hepatitis C
  • Pegylated-Interferon Alfa 2b (PEG-IFN)
  • +2 more
  • Birmingham, Alabama
  • +42 more
Nov 2, 2021

Polycythemia Vera Trial in Tianjin (Ruxolitinib, Pegylated interferon a-2b)

Recruiting
  • Polycythemia Vera
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
May 19, 2023

HIV, Hepatitis B, Hepatitis C Trial (Adefovir dipivoxil, Peginterferon-alfa-2A, Ribavirin)

Withdrawn
  • HIV Infections
  • +2 more
  • Adefovir dipivoxil
  • +3 more
  • (no location specified)
Oct 28, 2021

Hepatitis C, Chronic Trial (Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c)

Completed
  • Hepatitis C, Chronic
  • Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin
  • Combination of (a) pegylated interferon alfa-2b and (b) ribavirin
  • (no location specified)
Aug 24, 2020

Chronic Hepatitis B Virus Infection Trial in Worldwide (PEG-IFNa, BRII-835)

Not yet recruiting
  • Chronic Hepatitis B Virus Infection
  • Kingswood, New South Wales, Australia
  • +28 more
Jul 21, 2023

Myelofibrosis Trial in Salt Lake City (Pegylated interferon alpha2a)

Not yet recruiting
  • Myelofibrosis
  • Pegylated interferon alpha2a
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Sep 6, 2022

Hepatitis B, Chronic Trial in Worldwide (peginterferon alfa-2a [Pegasys])

Completed
  • Hepatitis B, Chronic
  • peginterferon alfa-2a [Pegasys]
  • San Francisco, California
  • +38 more
Oct 26, 2022

Cervical Dysplasia, HPV Infection Trial in Ulaanbaatar (gel Interferon arm, gel Interferon and interferon suppository arm)

Recruiting
  • Cervical Dysplasia
  • HPV Infection
  • gel Interferon arm
  • gel Interferon and interferon suppository arm
  • Ulaanbaatar, Mongolia
    National Cancer Center
Nov 14, 2023

Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

Recruiting
  • Lymphoma, B-Cell
  • Rituximab Biosimilar
  • Pegylated Interferon α-2b
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil)

Terminated
  • Hepatitis B, Chronic
  • Hillsborough, New Jersey
  • +11 more
Dec 28, 2022

Hepatitis B, Chronic Trial in Hefei (PEGylated recombinant human interferon alpha-2b injection)

Recruiting
  • Hepatitis B, Chronic
  • PEGylated recombinant human interferon alpha-2b injection
  • Hefei, Anhui, China
    The First Affiliated Hospital of Anhui Medical University
Jun 24, 2023

Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7 Trial in Buffalo (drug,

Completed
  • Metastatic Carcinoma in the Liver
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Feb 25, 2022

Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)

Active, not recruiting
  • Triple -Negative Breast Cancer
  • +4 more
  • Biopsy
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Aug 1, 2022

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Membranous Nephropathy Trial in Nice (Peginterferon Alfa-2A 180 MCG/ML Injectable Solution)

Not yet recruiting
  • Membranous Nephropathy
  • Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
  • Nice, France
    CHU de NICE
Jul 4, 2023